Pharmaceuticals Spain

Spain Oral GLP-1 Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Spain Oral GLP-1 Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Spain · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $68.7 Mn Placeholder estimate
Estimate 2025 $90.0 Mn 1.6% of the global market
Projected 2034 $1.02 Bn 1,028.4% Adds $925.1 Mn over 9 forecast years
CAGR 2025–2034 30.9% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Spain is 1.61% of the global market.
  • In Europe, the largest is Germany at $185.2 Mn.
  • Fastest growing: Russia at 31.8% a year.
  • Spain ranks 5th of 6 by size in Europe.

Market size projection

Spain

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$925.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Oral GLP-1 Drugs Market market size by year, Spain
YearMarket sizeChange that yearSince 2025
2024 (estimate) $68.7 Mn — —
2025 (base) $90.0 Mn +$21.2 Mn —
2026 (forecast) $117.8 Mn +$27.8 Mn +30.9%
2027 (forecast) $154.1 Mn +$36.4 Mn +71.3%
2028 (forecast) $201.8 Mn +$47.6 Mn +124.3%
2029 (forecast) $264.1 Mn +$62.3 Mn +193.6%
2030 (forecast) $345.7 Mn +$81.6 Mn +284.3%
2031 (forecast) $452.6 Mn +$106.8 Mn +403.1%
2032 (forecast) $592.4 Mn +$139.8 Mn +558.5%
2033 (forecast) $775.5 Mn +$183.1 Mn +762%
2034 (forecast) $1.02 Bn +$239.6 Mn +1,028.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Spain Oral GLP-1 Drugs Market Analysis at a glance
Market size, 2025$90.0 Mn placeholder estimate
Forecast, 2034$1.02 Bn placeholder estimate
Growth (CAGR), 2025–203430.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, application and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics, Viking Therapeutics (see all)
Regulator in SpainAEMPSSource: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Spain Oral GLP-1 Drugs Market Analysis Executive Summary

Oral GLP-1 drugs deliver GLP-1 based therapy as a tablet instead of an injection, making treatment easier for people with diabetes or obesity.

Key segments of the oral GLP-1 Drugs market include drug (Oral Semaglutide, Orforglipron and Danuglipron) and application (Type 2 Diabetes and Obesity).

Bar chart: Spain Oral GLP-1 Drugs market size, 2024–2034, placeholder estimates. $68.7 Mn in 2024, $90.0 Mn in 2025 and $1.02 Bn in 2034, 30.9% CAGR.
Spain Oral GLP-1 Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Spain Oral GLP-1 Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the oral GLP-1 Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the oral GLP-1 Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Oral GLP-1 Drugs Market in Spain

The oral GLP-1 Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Oral GLP-1 Drugs Market in Spain

Oral GLP-1 Drugs in Spain: rules, payment and health figures

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.⁠[1] The National Health System (SNS), run by the regions, gives universal public care.⁠[2] Obesity (adults): 15.3% of adults in 2024, the latest WHO figure for Spain.⁠[3]

[1] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[2] Spanish Ministry of Health. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oral GLP-1 Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Oral GLP-1 Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Oral GLP-1 Drugs in context

Spain compared

  • Obesity (adults): 15.3% of adults (2024). World: 16.2% of adults (2024). 8th highest of the 13 countries we cover in Europe.[1]
  • Health spending per person: 3,107 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 13 countries we cover in Europe.[2]
  • Doctors: 4.29 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 13 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Inside Spain

Quick answers

Frequently asked questions

How big is the Oral GLP-1 Drugs market in Spain?
Placeholder estimate: about $90.0 Mn in 2025, rising to about $1.02 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Oral GLP-1 Drugs market in Spain growing?
Placeholder estimate: about 30.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Oral GLP-1 Drugs market report cover?
The report splits the market by drug (Oral Semaglutide, Orforglipron, Danuglipron, Others), application (Type 2 Diabetes, Obesity) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Oral GLP-1 Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics and Viking Therapeutics.
What is driving the Oral GLP-1 Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market.
Who regulates Oral GLP-1 Drugs in Spain?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices. Source: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
How is healthcare paid for in Spain?
The National Health System (SNS), run by the regions, gives universal public care. Source: Spanish Ministry of Health. Checked 14 Nov 2026.
What does WHO report for Spain?
Obesity (adults): 15.3% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
How many people in Spain are 65 or older?
21.6% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
How much research is published on Oral GLP-1 Drugs?
PubMed lists 65 papers on Oral GLP-1 Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Spain

See all

Related on obesity and diabetes

See the topic